Here we sought to identify and characterize cancer cell lines with complete loss of either TSC1 or TSC2, and then to examine their sensitivity to a broad panel of kinase inhibitors, with a goal to identify additional inhibitors beyond rapalogs. The gene discussed is TSC1; the disease is cancer.